 A phase-four clinical trial is currently recruiting participants to investigate whether Aldurazyme passes through breastmilk and whether it has any effect on nursing infants.Aldurazyme was the first drug approved by the United States Food and Drug Administration to be marketed as a treatment for MPS I.It was approved in April 2003.